The chemotherapy-free regimen achieved higher remission, better survival, and stronger molecular responses than the ...

The global acute lymphocytic leukemia (ALL) market is set for substantial growth from 2025 to 2035, fueled by advances in chemotherapy, targeted therapies, and immunotherapy. Particularly affecting ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

Acute myeloid leukemia (AML) is a rare, fast-growing cancer that starts in the bone marrow. The disease promotes the ...

A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by ...

For adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), the steepest barriers to high-quality care ...

Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.

Scientists at the University College London (UCL) have developed a novel therapy that helps treat patients with T cell acute ...

The report charts major advances in precision oncology and immunotherapy but also reveals stagnant survival for several ...

The parents of a 15-month-old girl who spent months without a diagnosis finally learned their daughter had a rare subtype of ...

Researchers assessed survival outcomes for Asian patients with newly diagnosed AML vs White patients. Researchers determined Asian patients with newly diagnosed AML may have superior OS outcomes ...

Over the past year, coordinated reporting by the BBC, CBS News, and multiple public broadcasters across Europe has uncovered ...